[SCHEDULE 13G/A] PLUS THERAPEUTICS, Inc. SEC Filing

Rhea-AI Filing Summary

Plus Therapeutics, Inc. Schedule 13G/A filed by S.H.N. Financial Investments Ltd. reports beneficial ownership of 1,500,000 shares of common stock, representing 1.51% of the class based on 99,264,526 shares outstanding. The amendment references a prior Schedule 13G filed March 18, 2025, which covered 1,209,754 shares purchased March 4, 2025, indicating the reporter increased its position to the 1.5 million share level.

The filer is S.H.N. Financial Investments Ltd., organized in Israel, with Nir Shamir identified as CEO of the reporting entity and noted as potentially deemed to beneficially own the reported shares, though he disclaims ownership for other purposes. The filing certifies the shares were not acquired to influence control of the issuer.

Positive

• Increased disclosed position from 1,209,754 to 1,500,000 shares, providing updated transparency
• Filing reports ownership below 5%, indicating no control intent and routine disclosure status
• Certifies shares were not acquired to influence control, addressing governance concerns

Negative

• None.

Insights

Financial Analyst

TL;DR: A small institutional stake increased to 1.51%, not large enough to signal control or trigger major market impact.

S.H.N. Financial Investments raised its disclosed position from 1,209,754 to 1,500,000 shares, a disclosure that updates ownership but remains below 5% and therefore unlikely to change governance or strategic direction. The filing uses the issuer's Form S-1 share count of 99,264,526 to compute percentage ownership. For investors, this is a routine beneficial ownership update rather than a material corporate event.

Corporate Governance Expert

TL;DR: Ownership disclosure is compliant and routine; CEO of reporting entity is disclosed but disclaims broader beneficial ownership.

The Schedule 13G/A states the reporting entity is an FI organized in Israel and includes the required certification that the stake was not acquired to influence control. Identification of Nir Shamir as CEO of the reporting entity and the disclaimer about his beneficial ownership are appropriate governance disclosures. No group affiliations or control intents are claimed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Plus Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

72941H509

(CUSIP Number)

08/14/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 72941H509

1

Names of Reporting Persons

S.H.N. Financial Investments Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,500,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.51 %

12

Type of Reporting Person (See Instructions)

FI

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Plus Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2710 Reed Rd., Suite 160, Houston, TX 77051
Item 2.
(a)	Name of person filing: S.H.N. Financial Investments Ltd.
(b)	Address or principal business office or, if none, residence: Herzliya Hills Arik Einstein 3, Israel, 4610301
(c)	Citizenship: Israel
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 72941H509
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,500,000 This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on March 18, 2025, covering 1,209,754 shares of Common Stock purchased on March 4, 2025. The amounts in Row (5), (7) and (9) represent 1,500,000 shares of Common Stock. The percentage set forth on Row (11) of the cover page for the reporting person is based on 99,264,526 shares of Common Stock outstanding as of August 8, 2025, based on the Issuer's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 12, 2025. Nir Shamir is the Chief Executive Officer of the Reporting Person. As such, Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein. To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities for all other purposes.
(b)	Percent of class: 1.51%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,500,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,500,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

S.H.N. Financial Investments Ltd.

Signature:	/s/ Nir Shamir
Name/Title:	Nir Shamir, Chief Executive Officer
Date:	08/14/2025

FAQ

How many Plus Therapeutics (PSTV) shares does S.H.N. Financial now disclose owning?

The filer reports beneficial ownership of 1,500,000 shares, equal to 1.51% of the outstanding common stock based on 99,264,526 shares.

When did S.H.N. Financial previously report purchases of PSTV shares?

The amendment references a Schedule 13G filed March 18, 2025, covering 1,209,754 shares purchased on March 4, 2025.

Does this filing indicate S.H.N. Financial seeks to control Plus Therapeutics (PSTV)?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.

Who is identified as potentially having beneficial ownership through S.H.N. Financial?

Nir Shamir is identified as Chief Executive Officer of the reporting person and may be deemed to beneficially own the securities, though he disclaims ownership for other purposes.

What classification is S.H.N. Financial Investments Ltd. under the filing?

The reporting person is classified as an FI and is organized in Israel.